Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study

References

• World Health Organization. Schizophrenia fact sheet; 2016. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed 111, 2021.
   Google Scholar
• PalmerB, PankratzV, BostwickJ. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–253. doi:10.1001/archpsyc.62.3.24715753237
   PubMed Web of Science ®Google Scholar
• SahaS, ChantD, McGrathJ. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry. 2007;64(10):1123–1131. doi:10.1001/archpsyc.64.10.112317909124
   PubMed Web of Science ®Google Scholar
• DaumitG, AnthonyC, FordD, et al. Pattern of mortality in a sample of Maryland residents with severe mental illness. Psychiatry Res. 2010;176(2–3):242–245. doi:10.1016/j.psychres.2009.01.00620207013
   PubMed Web of Science ®Google Scholar
• TandbergM, SundetK, AndreassenO, MelleI, UelandT. Occupational functioning, symptoms and neurocognition in patients with psychotic disorders: investigating subgroups based on social security status. Soc Psychiatry Psychiatr Epidemiol. 2013;48(6):863–874. doi:10.1007/s00127-012-0598-223064396
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi:10.1016/S0140-6736(15)60692-426063472
   PubMed Web of Science ®Google Scholar
• EvensenS, WisløffT, LystadJ, BullH, UelandT, FalkumE. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull. 2015;42(2):476–483. doi:10.1093/schbul/sbv14126433216
   PubMed Web of Science ®Google Scholar
• CorrellCU, SolmiM, VeroneseN, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi:10.1002/wps.2042028498599
   PubMed Web of Science ®Google Scholar
• HjorthojC, SturupAE, McGrathJJ, NordentoftM. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301. doi:10.1016/S2215-0366(17)30078-028237639
   PubMed Web of Science ®Google Scholar
• BowieCR, LeungWW, ReichenbergA, McClureMM, HarveyPD. Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry. 2008;63(5):505–511. doi:10.1016/j.biopsych.2007.05.02217662256
   PubMed Web of Science ®Google Scholar
• RobinsonDG, WoernerMG, McMenimanM, MendelowitzA, BilderRM. Symptomatic and functional recover from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–479. doi:10.1176/appi.ajp.161.3.47314992973
   PubMed Web of Science ®Google Scholar
• MilevP, HoBC, ArndtS, AndreasenNC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506. doi:10.1176/appi.ajp.162.3.49515741466
   PubMed Web of Science ®Google Scholar
• GitlinM, NuechterleinK, SubotnikKL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835–1842. doi:10.1176/appi.ajp.158.11.183511691689
   PubMed Web of Science ®Google Scholar
• IshibashiT, HorisawaT, TokudaK, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171–181. doi:10.1124/jpet.110.16734620404009
   PubMed Web of Science ®Google Scholar
• ZhengW, CaiDB, YangXH, et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;103:244–251. doi:10.1016/j.jpsychires.2018.06.00529906709
   PubMed Web of Science ®Google Scholar
• CitromeL, CucchiaroJ, SarmaK, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–176. doi:10.1097/YIC.0b013e32835281ef22395527
   PubMed Web of Science ®Google Scholar
• StahlSM, CucchiaroJ, SimonelliD, HsuJ, PikalovA, LoebelA. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(05):507–515. doi:10.4088/JCP.12m0808423541189
   PubMed Web of Science ®Google Scholar
• LoebelA, CucchiaroJ, XuJ, SarmaK, PilalovA, KaneJM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147:95–102. doi:10.1016/j.schres.2013.03.01323583011
   PubMed Web of Science ®Google Scholar
• CorrellCU, CucchiaroJ, SilvaR, HsuJ. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016;21(5):393–402. doi:10.1017/S109285291500091727048911
   PubMed Web of Science ®Google Scholar
• HiguchiT, IshigookaJ, IyoM, HagiK. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: results of a 26-week open-label extension study. Asia Pac Psychiatry. 2020;12(1):e12377. doi:10.1111/appy.1237731837113
   PubMed Web of Science ®Google Scholar
• IyoM, IshigookaJ, NakamuraM, et al. Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2021;75(7):227–235. doi:10.1111/pcn.13221
   Web of Science ®Google Scholar
• LoebelA, CucchiaroJ, SarmaK, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–109. doi:10.1016/j.schres.2013.01.00923415311
   PubMed Web of Science ®Google Scholar
• KayS, FiszbeinA, OplerL. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.2613616518
   PubMed Web of Science ®Google Scholar
• GuyW. ECDEU Assessment Manual for Psychopharmacology, (revised), (ADM) 76–338 edn. Rockville, MD: National Institute of Mental Health; 1976.
   Google Scholar
• PosnerK, BrownGK, StanleyB, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. doi:10.1176/appi.ajp.2011.1011170422193671
   PubMed Web of Science ®Google Scholar
• InadaT, BeasleyC, TanakaY, WalkerD. Extrapyramidal symptom profiles assessed with the drug-induced extrapyramidal symptom scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003;18:39–48. doi:10.1097/00004850-200301000-0000712490774
   PubMed Web of Science ®Google Scholar
• AddingtonD, AddingtonJ, Maticka-TyndaleE. Assessing depression in schizophrenia: the calgary depression scale. Br J Psychiatry Suppl. 1993;163(S22):39–44. doi:10.1192/S0007125000292581
   Google Scholar
• LindenmayerJP, Bernstein-HymanR, GrochowskiS. A new five factor model of schizophrenia. Psychiatr Q. 1994;65(4):299–322. doi:10.1007/BF023543067831416
   PubMedGoogle Scholar
• RabinR, de CharroF. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343. doi:10.3109/0785389010900208711491192
   PubMed Web of Science ®Google Scholar
• MeltzerH, CucchiaroJ, SilvaR, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–967. doi:10.1176/appi.ajp.2011.1006090721676992
   PubMed Web of Science ®Google Scholar
• NasrallahH, SilvaR, PhillipsD, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–677. doi:10.1016/j.jpsychires.2013.01.02023421963
   PubMed Web of Science ®Google Scholar
• ChowCL, KadouhNK, BostwickRJ, VanderBergAM. Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. Pharmacotherapy. 2020;40(6):565–574. doi:10.1002/phar.240432342999
   PubMed Web of Science ®Google Scholar
• KroezeWK, HufeisenSJ, PopadakBA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526. doi:10.1038/sj.npp.130002712629531
   PubMed Web of Science ®Google Scholar
• VancampfortD, StubbsB, MitchellAJ. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347. doi:10.1002/wps.2025226407790
   PubMed Web of Science ®Google Scholar
• LoebelA, SilvaR, GoldmanR, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016;77(12):1672–1680. doi:10.4088/JCP.16m1069827454547
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]; 2014. Available from: www.nice.org.uk/guidance/cg178. Accessed 111, 2021.
   Google Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 3rd ed. Arlington, VA: American Psychiatric Publishing; 2020.
   Google Scholar
• BuchananRW, KreyenbuhlJ, KellyDL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. doi:10.1093/schbul/sbp11619955390
   PubMed Web of Science ®Google Scholar
• ArndtS. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Arch Gen Psychiatry. 1995;52(5):352–360. doi:10.1001/archpsyc.1995.039501700260047726715
   PubMed Web of Science ®Google Scholar
• HeatonRK, GladsjoJA, PalmerBW, KuckJ, MarcotteTD, JesteDV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24–32. doi:10.1001/archpsyc.58.1.2411146755
   PubMed Web of Science ®Google Scholar
• AustinSF, MorsO, Budtz-JørgensenE, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr Res. 2015;168(1–2):84–91. doi:10.1016/j.schres.2015.07.02126265299
   PubMed Web of Science ®Google Scholar
• HallidayJ, FarringtonS, MacdonaldS, et al. Nithsdale schizophrenia surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181(5):422–427. doi:10.1192/bjp.181.5.42212411269
   PubMed Web of Science ®Google Scholar
• HasnainM, FredricksonSK, ViewegWV, PandurangiAK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209–216. doi:10.1007/s11892-010-0112-820425584
   PubMed Web of Science ®Google Scholar
• HarveyPD, SiuCO, HsuJ, CucchiaroJ, MaruffP, LoebelA. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23(11):1373–1382. doi:10.1016/j.euroneuro.2013.08.00324035633
   PubMed Web of Science ®Google Scholar
• NasrallahHA, CucchiaroJB, MaoY, PikalovAA, LoebelAD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo‐controlled studies. CNS Spectr. 2015;20(2):140‐147. doi:10.1017/S1092852914000285
   Web of Science ®Google Scholar
• TandonR, CucchiaroJ, PhillipsD, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30(1):69–77. doi:10.1177/026988111562046026645209
   PubMed Web of Science ®Google Scholar